Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Nature

Volumn 508, Issue 7498, 2014, Pages 55-62

  Doria Rose, Nicole A ^a   Schramm, Chaim A ^b   Gorman, Jason ^a   Moore, Penny L ^c,d,e   Bhiman, Jinal N ^c,d   DeKosky, Brandon J ^f   Ernandes, Michael J ^a   Georgiev, Ivelin S ^a   Kim, Helen J ^g   Pancera, Marie ^a   Staupe, Ryan P ^a   Altae Tran, Han R ^a   Bailer, Robert T ^a   Crooks, Ema T ^h   Cupo, Albert ⁱ   Druz, Aliaksandr ^a   Garrett, Nigel J ^e   Hoi, Kam H ^f   Kong, Rui ^a   Louder, Mark K ^a   Longo, Nancy S ^a   McKee, Krisha ^a   Nonyane, Molati ^c   O'Dell, Sijy ^a   Roark, Ryan S ^a   Rudicell, Rebecca S ^a   Schmidt, Stephen D ^a   Sheward, Daniel J ^j   Soto, Cinque ^a   Wibmer, Constantinos Kurt ^c,d   Yang, Yongping ^a   Zhang, Zhenhai ^b   Mullikin, James C ^k,l   Binley, James M ^h   Sanders, Rogier W ^m   Wilson, Ian A ^g   Moore, John P ⁱ   Ward, Andrew B ^g   Georgiou, George ^f,n   Williamson, Carolyn ^e,j   Karim, Salim S Abdool ^b,e   Morris, Lynn ^c,d,e   Kwong, Peter D ^a   Shapiro, Lawrence ^a,b   Mascola, John R ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f The University of Texas at Austin   (United States)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

^h TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF TEXAS AT AUSTIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; TYROSINE; UNCLASSIFIED DRUG; V1V2 ANTIBODY; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 160;

ANTIBODY ISOLATION; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL SELECTION; COMPLEMENTARITY DETERMINING REGION; CRYSTAL STRUCTURE; DISULFIDE BOND; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; VDJ RECOMBINATION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; BINDING SITE; CELL LINEAGE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; EPITOPE MAPPING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIGENS, CD4; B-LYMPHOCYTES; BINDING SITES; CELL LINEAGE; COMPLEMENTARITY DETERMINING REGIONS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EVOLUTION, MOLECULAR; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84899991983     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13036     Document Type: Article

References (83)

1. Haynes, B. F., Kelsoe, G., Harrison, S. C. & Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnol. 30, 423-433 (2012).
2. Kong, L. & Sattentau, Q. J. Antigenicity and immunogenicity in HIV-1 antibodybased vaccine design. J. AIDS Clinic. Res. (Suppl. 8) 003 (2012).
3. Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244 (2013).
4. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
5. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
6. + T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
7. Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83, 10269-10274 (2009).
8. Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
9. Doria-Rose, N. A. et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636 (2010).
10. Glanville, J. et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc. Natl Acad. Sci. USA 106, 20216-20221 (2009).
11. Briney, B.S., Willis, J. R., McKinney, B. A. & Crowe, J. E. Jr. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naive and memory repertoires that extends across individuals. Genes Immun. 13, 469-473 (2012).
12. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
13. Zhu, J. et al. Mining the antibodyome for HIV-1-Neutralizing antibodies with nextgeneration sequencing and phylogenetic pairing of heavy/light chains. Proc. Natl Acad. Sci. USA 110, 6470-6475 (2013).
14. Zhu, J. et al. Somatic populations of PGT135-137 HIV-1-Neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front. Microbiol. 3, 315 (2012).
15. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
16. Walker, L. M. et al. A limited number of antibody specificities mediate broad and potent serumneutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028 (2010).
17. Lynch, R. M. et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85, 905-915 (2011).
18. Georgiev, I. S. et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013).
19. Walker, L. M. et al. Broad and potent neutralizing antibodies froman African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
20. Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
21. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
22. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
23. Pancera, M. et al. Structural basis for diverse N-glycan recognition by HIV-1- neutralizing V1-V2-directed antibody PG16. Nature Struct. Mol. Biol. 20, 804-813 (2013).
24. Julien, J. P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl Acad. Sci. USA 110, 4351-4356 (2013).
25. Moore, P. L. et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targetinga quaternary epitope including residues in the V2loop. J. Virol. 85, 3128-3141 (2011).
26. Moore, P. L. et al. Multiple pathways of escape from HIV broadly cross-Neutralizing V2-dependent antibodies. J. Virol. 87, 4882-4894 (2013).
27. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
28. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
29. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. & Foeller, C. Sequences of Proteins of Immunological Interest (U.S. Department of Health and Human Services, National Institutes of Health, 1991).
30. Pancera, M. & Wyatt, R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332, 145-156 (2005).
31. Tong, T., Crooks, E. T., Osawa, K. & Binley, J. M. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J. Virol. 86, 3574-3587 (2012).
32. Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490 (2013).
33. Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483 (2013).
34. Doria-Rose, N. A. et al. A short segment of the HIV-1 gp120 V1/V2 region is amajor determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 86, 8319-8323 (2012).
35. DeKosky, B. J. et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nature Biotechnol. 31, 166-169 (2013).
36. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
37. Rolland, M. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
38. Overbaugh, J. & Morris, L. The antibody response against HIV-1. Cold Spring Harb. Perspect. Med. 2, a007039 (2012).
39. Briney, B. S., Willis, J. R. & Crowe, J. E. Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 7, e36750 (2012).
40. Lefranc, M. P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27, 55-77 (2003).
41. Wardemann, H. et al. Predominant autoantibody production by early humanBcell precursors. Science 301, 1374-1377 (2003).
42. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
43. Kwong, P. D. & Mascola, J. R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
44. Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
45. Huang, J. et al. Isolation of human monoclonal antibodies fromperipheral blood B cells. Nature Protocols 8, 1907-1915 (2013).
46. Shu, Y. et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25, 1398-1408 (2007).
47. Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395-405 (2009).
48. Kraus, M. H. et al. A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology 397, 346-357 (2010).
49. Salazar-Gonzalez, J. F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952-3970 (2008).
50. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. & Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).
51. van Loggerenberg, F. et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3, e1954 (2008).
52. Doria-Rose, N. et al. High throughput HIV-1 microneutralization assay. Protocol Exchange http://dx.doi.org/10.1038/protex.2013.069 (2013).
53. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
54. Julien, J. P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4binding via recognition of the HIV-1gp120V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013).
55. Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41-60 (2005).
56. Lander, G. C. et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95-102 (2009).
57. Voss, N. R., Yoshioka, C. K., Radermacher, M., Potter, C. S. & Carragher, B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205-213 (2009).
58. Sorzano, C. O. et al. A clustering approach to multireference alignment of single-particle projections in electron microscopy. J. Struct. Biol. 171, 197-206 (2010).
59. van Heel, M., Harauz, G., Orlova, E. V., Schmidt, R. & Schatz, M. A new generation of the IMAGIC image processing system. J. Struct. Biol. 116, 17-24 (1996).
60. Ludtke, S. J., Baldwin, P. R. & Chiu, W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
61. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (2007).
62. Alamyar, E., Giudicelli, V., Li, S., Duroux, P. & Lefranc, M. P. IMGT/HighV-QUEST: the IMGT web portal for immunoglobulin (IG) or antibody and T cell receptor (TR) analysis from NGS high throughput and deep sequencing. Immunome Res. 8 (2012).
63. Li, W., Jaroszewski, L. & Godzik, A. Clustering of highly homologous sequences to reduce the size of large protein databases. Bioinformatics 17, 282-283 (2001).
64. Souto-Carneiro, M. M., Longo, N. S., Russ, D. E., Sun, H. W. & Lipsky, P. E. Characterization of the human Ig heavy chain antigen binding complementarity determining region 3 using a newly developed software algorithm, JOINSOLVER. J. Immunol. 172, 6790-6802 (2004).
65. Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-2739 (2011).
66. Waddell, P. J. & Steel, M. A. General time-reversible distances with unequal rates across sites: mixing gamma and inverse Gaussian distributions with invariant sites. Mol. Phylogenet. Evol. 8, 398-414 (1997).
67. Ashkenazy, H. et al. FastML: a web server for probabilistic reconstruction of ancestral sequences. Nucleic Acids Res. 40, W580-W584 (2012).
68. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188-1190 (2004).
69. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
70. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
71. Adams, P. D. et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Synchrotron Radiat. 11, 53-55 (2004).
72. Davis, I. W., Murray, L. W., Richardson, J. S. & Richardson, D. C. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32, W615-W619 (2004).
73. DeLano, W. L. The PyMOL Molecular Graphics System. http://www.pymol.org (DeLano Scientific, San Carlos, California, 2002).
74. Pettersen, E. F. et al. UCSFChimera-a visualization systemfor exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
75. Tran, E. E. et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8, e1002797 (2012).
76. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
77. Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011).
78. Soto, C. S., Fasnacht, M., Zhu, J., Forrest, L. & Honig, B. Loop modeling: Sampling, filtering, and scoring. Proteins 70, 834-843 (2008).
79. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2-approximately maximumlikelihood trees for large alignments. PLoS ONE 5, e9490 (2010).
80. Murrell, B. et al. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 8, e1002764 (2012).
81. Kosakovsky Pond, S. L., Poon, A. F., Leigh Brown, A. J. & Frost, S. D. A maximum likelihood method for detecting directional evolution in protein sequences and its application to influenza A virus. Mol. Biol. Evol. 25, 1809-1824 (2008).
82. Pond, S. L., Frost, S. D. & Muse, S. V. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21, 676-679 (2005).
83. Gao, F. et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70, 7013-7029 (1996).